Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.68%. Elsewhere, the Dow gained 1.05%, while the tech-heavy Nasdaq added 0.33%. Coming into today, shares of the drugmaker had lost 0.71% in the past month. In that same time, the Medical sector gained 3.35%, while the S&P 500 gained 1.8%. The upcoming earnings release of Pfizer will be of great interest to investors. On that day, Pfizer is projected to report earnings of $0.64 per share, which would represent year-over-year growth of 1.59%. At the same time, our most recent consensus estimate is projecting a revenue of $17.96 billion, reflecting a 1.13% rise from the equivalent quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.14 per share and a revenue of $62.94 billion, representing changes of +0.96% and -1.08%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.59% increase. Pfizer is holding a Zacks Rank of #3 (Hold) right now. With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 8.06. This indicates a discount in contrast to its industry's Forward P/E of 12.95. The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 186, which puts it in the bottom 25% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Zacks Naming Top 10 Stocks for 2026Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks